Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors
- PMID: 16871231
- DOI: 10.1038/sj.gt.3302831
Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors
Abstract
An increasing number of oncolytic viruses have been developed and studied for cancer therapy. In response to needs for non-invasive monitoring and imaging of oncolytic virotherapy, several different approaches, including a positron emission tomography-based method, a method using secreted marker peptides, and optical imaging-based methods, have been reported. Among these modalities, we utilized the luciferase-based bioluminescent assay/imaging systems to determine the kinetics and dynamics of a productive viral infection. The replication cycle of herpes simplex virus type 1 (HSV-1) is punctuated by a temporal cascade of three classes of viral genes: immediate-early (IE), early (E) and late (L) genes. U(L)39- and gamma(1)34.5-deleted, replication-conditional HSV-1 mutants that express firefly luciferase under the control of the IE4/5 or strict-late gC promoters were generated. These oncolytic viruses were examined in cultured cells and a mouse tumor model. IE promoter- and strict-late promoter-mediated luciferase expression was confirmed to indicate viral infection and replication, respectively. Incorporation of a strict-late promoter-driven luciferase cassette into oncolytic HSV-1 vectors would be useful for assessing tumor oncolysis in preclinical tumor treatment studies.
Similar articles
-
Replication-Competent Controlled Herpes Simplex Virus.J Virol. 2015 Oct;89(20):10668-79. doi: 10.1128/JVI.01667-15. Epub 2015 Aug 12. J Virol. 2015. PMID: 26269179 Free PMC article.
-
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.Cancer Res. 2001 Apr 1;61(7):2983-95. Cancer Res. 2001. PMID: 11306477
-
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.Gene Ther. 2006 Apr;13(8):705-14. doi: 10.1038/sj.gt.3302717. Gene Ther. 2006. PMID: 16421599
-
Oncolytic herpes simplex virus engineering and preparation.Methods Mol Biol. 2012;797:1-19. doi: 10.1007/978-1-61779-340-0_1. Methods Mol Biol. 2012. PMID: 21948465 Review.
-
Oncolytic virus therapy using genetically engineered herpes simplex viruses.Front Biosci. 2008 Jan 1;13:2060-4. doi: 10.2741/2823. Front Biosci. 2008. PMID: 17981691 Review.
Cited by
-
Theranostic potential of oncolytic vaccinia virus.Theranostics. 2012;2(4):363-73. doi: 10.7150/thno.3724. Epub 2012 Apr 5. Theranostics. 2012. PMID: 22509200 Free PMC article.
-
"Armed" oncolytic herpes simplex viruses for brain tumor therapy.Cell Adh Migr. 2008 Jul-Sep;2(3):208-13. doi: 10.4161/cam.2.3.6353. Epub 2008 Jul 28. Cell Adh Migr. 2008. PMID: 19262110 Free PMC article.
-
NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy.Clin Cancer Res. 2022 Apr 1;28(7):1460-1473. doi: 10.1158/1078-0432.CCR-21-2347. Clin Cancer Res. 2022. PMID: 35022322 Free PMC article. Clinical Trial.
-
Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains.Virology. 2018 Jan 1;513:129-135. doi: 10.1016/j.virol.2017.10.011. Epub 2017 Oct 22. Virology. 2018. PMID: 29069622 Free PMC article.
-
Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.Cancer Gene Ther. 2010 Sep;17(9):655-63. doi: 10.1038/cgt.2010.22. Epub 2010 May 28. Cancer Gene Ther. 2010. PMID: 20508670 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous